SBHW-PREDICT (The role of PRoteomics, gEnetics, and Directed Imaging using CT)

SBHW-PREDICT（蛋白质组学、遗传学和 CT 定向成像的作用）

基本信息

批准号：
9109508
负责人：
Shaista Malik
金额：
$ 69.45万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-15 至 2020-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9109508
关键词：
Address Biological Biological Markers Blood Tests Calcium Cardiac Cardiovascular system Cells Cessation of life Chemotaxis Clinical Coronary Coronary artery Coronary heart disease Data Discrimination Disease Early treatment Eotaxin Event Family Family history of Fibrosis Freezing Funding Genetic Genetic Markers Genetic Predisposition to Disease Genetic Risk Genetic screening method Health Heart Heart Diseases Homeostasis Image Imaging Device Incidence Individual Inflammation Interdisciplinary Study Interleukin-6 Medicare Medicare claim Myocardial Infarction Outcome Participant Pathway interactions Phenotype Plasma Plasma Cells Population Predictive Value Predisposition Prevention Proteomics Recording of previous events Research Risk Risk Assessment Risk Factors Role Sampling Serum Signal Transduction Stable Disease Stress Survivors Testing Time Troponin United States National Institutes of Health Vascular calcification X-Ray Computed Tomography adiponectin alpha-Fetoproteins base circulating biomarkers cohort density experience follow-up genetic profiling heart disease risk imaging biomarker improved indexing lipoprotein-associated phospholipase A(2)mortality non-invasive imaging novel marker premature prevent prognostic value screening

项目摘要

DESCRIPTION (provided by applicant): In our proposed study, SBHW-PREDICT (The role of PRoteomics, gEnetics, and Directed Imaging using CT), we will assess whether identification of at-risk individuals, using imaging markers, a biomarker profile or a combination of the two, improves reclassification and discrimination over traditional risk factors, particularly in those wth either a family history of coronary heart disease (CHD) or higher genetic predisposition for CHD. We have used data from 1312 participants of the first NIH-funded study of predictive value of CAC, the South Bay Heart Watch (SBHW) study, to calculate plaque density. In preliminary analyses, we have found that higher plaque density is related to lower incidence of CVD events in this cohort. In the proposed study, we will use serum and cell samples collected at baseline, 20 years ago, from the SBHW and retrospectively assess outcomes using administrative data from Medicare and the National Death Index to address the following aims and objectives: 1) Using Medicare Claims and National Death Index data assess prognostic value of baseline CAC, as well as coronary calcium density for long-term (20 year) CHD event rate; 2) Using serum and cell samples collected at baseline, assess whether a multi-biomarker approach using circulating markers from different biological pathways would have additional reclassification value over traditional risk factors; 3) Determine whether compared to family history a CHD genetic risk score is more predictive of events; and 4) Determine whether a genetic score modifies the prognostic value of an imaging marker (CAC) or a multiple biomarker score or a combination of the two in those at higher predisposition (based on either family history or genetic score) for CHD versus those at low genetic risk. The experience of our multidisciplinary research team, unique 20 year follow-up period after baseline CAC, linkage to Medicare claims data and Death Index data, genetic and biomarker profiles using frozen serum and cell samples, and follow-up of the original cohort survivors are major strengths of this proposal. Results of thi project will assess the utility of a complementary genetic marker, multi-biomarker, and imaging approach to risk assessment.

描述（由申请人提供）：在我们提出的研究 SBHW-PREDICT（蛋白质组学、基因学和使用 CT 的定向成像的作用）中，我们将评估是否使用成像标记、生物标记概况或两者的结合，改善了对传统危险因素的重新分类和区分，特别是对于那些有冠心病（CHD）家族史或具有较高冠心病遗传倾向的人。南湾心脏观察 (SBHW) 研究由 NIH 资助，对 1312 名参与者进行了首次 CAC 预测价值计算，以计算斑块密度。在初步分析中，我们发现较高的斑块密度与较低的 CVD 事件发生率相关。在拟议的研究中，我们将使用 20 年前从 SBHW 收集的基线血清和细胞样本，并使用 Medicare 和国家死亡指数的管理数据回顾性评估结果，以实现以下目的和目标：1)使用医疗保险索赔和国家死亡指数数据评估基线 CAC 以及冠状动脉钙密度对长期（20 年）CHD 事件发生率的预后价值；2) 使用基线收集的血清和细胞样本，评估是否采用多生物标志物方法与传统风险因素相比，使用来自不同生物途径的循环标记物将具有额外的重新分类价值；3) 确定与家族史相比，CHD 遗传风险评分是否更能预测事件；4) 确定遗传评分是否可以改变预后价值；对于冠心病易感性较高的患者（基于家族史或遗传评分），与遗传风险较低的患者相比，进行影像学标记物 (CAC) 或多种生物标记物评分或两者的组合我们的多学科研究团队的经验是独一无二的。基线 CAC 后 20 年的随访期、与医疗保险索赔数据和死亡指数数据的联系、使用冷冻血清和细胞样本的遗传和生物标志物概况以及对原始幸存者队列的随访是该提案的主要优势。项目将评估补充的效用遗传标记、多生物标记和风险评估的成像方法。